PACS Group, Inc. (PACS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
I rate PACS a Buy and value the shares at $49.58, about 17% above the August 31 closing price. Q2 revenue rose 9.1%, operating income grew 35.8%, and same-store occupancy reached 90.6%. Eduro adds 3,633 beds. My 2027 model includes $260 million of incremental revenue after a 27% haircut.
When investors look for stocks riding the aging of America, they might look at hospital chains, pharmacy benefit managers, or dividend-paying healthcare REITs.
The consensus price target hints at a 25.7% upside potential for PACS Group, Inc. (PACS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PACS Group NYSE: PACS reported second-quarter 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% from a year earlier, citing higher occupancy, improved skilled nursing patient mix and continued progress across acquired facilities as they mature within its operating model.
PACS Group, Inc. (PACS) Q2 2026 Earnings Call Transcript
PACS Group, Inc. (PACS) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.31 per share a year ago.
Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS) and Alignment Healthcare (ALHC). But which of these two companies is the best option for those looking for undervalued stocks?
Investors with an interest in Medical Services stocks have likely encountered both PACS Group, Inc. (PACS) and Alignment Healthcare (ALHC). But which of these two stocks presents investors with the better value opportunity right now?
PACS Group NYSE: PACS reported a strong start to 2026, with executives citing higher occupancy, improved skilled mix and continued progress integrating acquired facilities as drivers of first-quarter performance.
PACS Group (PACS) is reaffirmed as a 'Buy' for long-term investors, following a 257% rebound from oversold lows. PACS demonstrates robust credit health with $795M liquidity, 0.1x net leverage, and strong interest coverage, supporting aggressive organic and acquisition-driven growth. Guidance for FY26 includes 8% revenue growth and 22% adjusted EBITDA growth, with margin expansion driven by facility maturation and industry consolidation opportunities.